Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples